Attitudinal barriers to buprenorphine prescription and former waiver training
DOI:
https://doi.org/10.5055/jom.0827Keywords:
opioid use disorder, medication-assisted treatment, buprenorphine, stigmaAbstract
Objective: Opioid use disorder (OUD) can be effectively treated with buprenorphine maintenance. Recent changes in federal policy have removed the requirement for physicians to complete additional training to apply for a Drug Enforcement Administration (DEA) waiver to prescribe buprenorphine. At that time, few primary care providers (PCPs) had completed the training for a DEA waiver to prescribe buprenorphine. Our goal was to identify addressable barriers that may persist despite updates to federal legislation.
Design: A 42-item survey was distributed to 662 physicians and nurse practitioners at two academic medical centers with 100 respondents.
Setting: The survey was sent via email and administered anonymously through SurveyMonkey.
Patients and participants: All participants were PCPs, and all PCPs at the two academic medical centers were eligible to participate.
Interventions: PCPs responded to the survey by answering questions online.
Main outcome measures: PCPs answered questions regarding previous buprenorphine waiver training status, local OUD prevalence, the effectiveness of OUD treatment modalities, and previous barriers to training.
Results: Respondents were compared using descriptive statistics and logistic regression. Of the 100 respondents (response rate: 15 percent), 69 percent had not completed the training. Ninety-nine percent of PCPs agreed that OUD was an issue in their area, 94 percent saw patients with OUD, and 91 percent rated buprenorphine maintenance as a very effective treatment for OUD. Previously waivered and nonwaivered providers did not differ in their responses to these questions. Those who had been waivered were less likely to say they did not see enough patients with OUD to justify training (odds ratio [OR] 0.267, p = 0.005) and were less likely to express concern about allowing patients with OUD into their practice (OR 0.348, p = 0.020) than PCPs who had applied for the DEA waiver.
Conclusions: Despite nonwaivered PCPs recognizing OUD's prevalence, they were concerned about allowing patients with OUD into their practice and said there were not enough patients to justify training. This suggests that attitudinal barriers are the most appropriate target for current intervention.
References
Frazier W, Cochran G, Lo-Ciganic WH, et al.: Medication-assisted treatment and opioid use before and after overdose in Pennsylvania Medicaid. JAMA. 2017; 318(8): 750-752. DOI: https://doi.org/10.1001/jama.2017.7818
Kampman K, Jarvis M: American Society of Addiction Medicine (ASAM) national practice guideline for the use of medications in the treatment of addiction involving opioid use. J Addict Med. 2015; 9(5): 358-367. DOI: https://doi.org/10.1097/ADM.0000000000000166
Larochelle MR, Bernson D, Land T, et al.: Medication for opioid use disorder after nonfatal opioid overdose and association with mortality: A cohort study. Ann Intern Med. 2018; 169(3): 137-145. DOI: https://doi.org/10.7326/M17-3107
Fox AD, Masyukova M, Cunningham CO: Optimizing psychosocial support during office-based buprenorphine treatment in primary care: Patients' experiences and preferences. Subst Abus. 2016; 37(1): 70-75. DOI: 10.1080/08897077.2015.1088496. DOI: https://doi.org/10.1080/08897077.2015.1088496
Gunderson EW, Wang XQ, Fiellin DA, et al.: Unobserved versus observed office buprenorphine/naloxone induction: A pilot randomized clinical trial. Addict Behav. 2010; 35(5): 537-540. DOI: 10.1016/j.addbeh.2010.01.001. DOI: https://doi.org/10.1016/j.addbeh.2010.01.001
Dugosh K, Abraham A, Seymour B, et al.: A systematic review on the use of psychosocial interventions in conjunction with medications for the treatment of opioid addiction. J Addict Med. 2016; 10(2): 93-103. DOI: https://doi.org/10.1097/ADM.0000000000000193
Bart G: Maintenance medication for opiate addiction: The foundation of recovery. J Addict Dis. 2012; 31(3): 207-225. DOI: https://doi.org/10.1080/10550887.2012.694598
Connery HS: Medication-assisted treatment of opioid use disorder: Review of the evidence and future directions. Harv Rev Psychiatry. 2015; 23(2): 63-75. DOI: https://doi.org/10.1097/HRP.0000000000000075
Sordo L, Barrio G, Bravo MJ, et al.: Mortality risk during and after opioid substitution treatment: Systematic review and meta-analysis of cohort studies. BMJ. 2017; 357: J1550. DOI: https://doi.org/10.1136/bmj.j1550
Colson J, Helm S, Silverman SM: Office-based opioid dependence treatment. Pain Phys. 2012; 3S (3 Suppl.): ES231-ES236. DOI: https://doi.org/10.36076/ppj.2012/15/ES231
Mattick RP, Kimber J, Breen C, et al.: Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev. 2004; 2014(3): Cd002207. DOI: https://doi.org/10.1002/14651858.CD002207.pub4
Mauger S, Fraser R, Gill K: Utilizing buprenorphine-naloxone to treat illicit and prescription-opioid dependence. Neuropsychiatr Dis Treat. 2014; 10: 587-598. DOI: https://doi.org/10.2147/NDT.S39692
Jones CM, Campopiano M, Baldwin G, et al.: National and state treatment need and capacity for opioid agonist medication-assisted treatment. Am J Public Health. 2015; 105(8): e55-e63. DOI: https://doi.org/10.2105/AJPH.2015.302664
Fiscella K, Wakeman SE, Beletsky L: Buprenorphine deregulation and mainstreaming treatment for opioid use disorder: X the X waiver. JAMA Psychiatry. 2019; 76(3): 229-230. DOI: https://doi.org/10.1001/jamapsychiatry.2018.3685
Wakeman SE: Using science to battle stigma in addressing the opioid epidemic: Opioid agonist therapy saves lives. Am J Med. 2016; 129(5): 455-456. DOI: https://doi.org/10.1016/j.amjmed.2015.12.028
Wakeman SE, Barnett ML: Primary care and the opioid-overdose crisis—Buprenorphine myths and realities. N Engl J Med. 2018; 379(1): 1-4. DOI: https://doi.org/10.1056/NEJMp1802741
Luo Q, Erikson CE: Changes in waivered clinicians prescribing buprenorphine and prescription volume by patient limit. JAMA. 2023; 329(20): 1792-1794. DOI: 10.1001/jama.2023.5038. DOI: https://doi.org/10.1001/jama.2023.5038
Andrilla CHA, Coulthard C, Larson EH: Barriers rural physicians face prescribing buprenorphine for opioid use disorder. Ann Fam Med. 2017; 15(4): 359-362. DOI: https://doi.org/10.1370/afm.2099
DeFlavio JR, Rolin SA, Nordstrom BR, et al.: Analysis of barriers to adoption of buprenorphine maintenance therapy by family physicians. Rural Remote Health. 2015; 15: 3019. DOI: https://doi.org/10.22605/RRH3019
Duncan LG, Mendoza S, Hansen H: Buprenorphine maintenance for opioid dependence in public sector healthcare: Benefits and barriers. J Addict Med Ther Sci. 2015; 1(2): 31-36. DOI: https://doi.org/10.17352/2455-3484.000008
Gordon AJ, Kavanagh G, Krumm M, et al.: Facilitators and barriers in implementing buprenorphine in the Veterans health administration. Psychol Addict Behav. 2011; 25(2): 215-224. DOI: https://doi.org/10.1037/a0022776
Hutchinson E, Catlin M, Andrilla CH, et al.: Barriers to primary care physicians prescribing buprenorphine. Ann Fam Med. 2014; 12(2): 128-133. DOI: https://doi.org/10.1370/afm.1595
Allen B, Harocopos A, Chernick R: Substance use stigma, primary care, and the New York state prescription drug monitoring program. Behav Med. 2020; 46(1): 52-62. DOI: https://doi.org/10.1080/08964289.2018.1555129
Kennedy-Hendricks A, Busch SH, McGinty EE, et al.: Primary care physicians' perspectives on the prescription opioid epidemic. Drug Alcohol Depend. 2016; 165: 61-70. DOI: https://doi.org/10.1016/j.drugalcdep.2016.05.010
Lagisetty PA, Healy N, Garpestad C, et al.: Access to primary care clinics for patients with chronic pain receiving opioids. JAMA Netw Open. 2019; 2(7): e196928. DOI: https://doi.org/10.1001/jamanetworkopen.2019.6928
Tsai AC, Kiang MV, Barnett ML, et al.: Stigma as a fundamental hindrance to the United States opioid overdose crisis response. PLoS Med. 2019; 16(11): e1002969. DOI: https://doi.org/10.1371/journal.pmed.1002969
van Boekel LC, Brouwers EP, van Weeghel J, et al.: Stigma among health professionals towards patients with substance use disorders and its consequences for healthcare delivery: Systematic review. Drug Alcohol Depend. 2013; 131(1-2): 23-35. DOI: https://doi.org/10.1016/j.drugalcdep.2013.02.018
Huhn AS, Dunn KE: Why aren't physicians prescribing more buprenorphine? J Subst Abuse Treat. 2017; 78: 1-7. DOI: https://doi.org/10.1016/j.jsat.2017.04.005
Woods JS, Joseph H: Reducing stigma through education to enhance medication-assisted recovery. J Addict Dis. 2012; 31(3): 226-235. DOI: https://doi.org/10.1080/10550887.2012.694599
Martin SA, Chiodo LM, Bosse JD, et al.: The next stage of buprenorphine care for opioid use disorder. Ann Intern Med. 2018; 169(9): 628-635. DOI: https://doi.org/10.7326/M18-1652
Saloner B, Stoller KB, Alexander GC: Moving addiction care to the mainstream—Improving the quality of buprenorphine treatment. N Engl J Med. 2018; 379(1): 4-6. DOI: https://doi.org/10.1056/NEJMp1804059
Wakeman SE, Kanter GP, Donelan K: Institutional substance use disorder intervention improves general internist preparedness, attitudes, and clinical practice. J Addict Med. 2017; 11(4): 308-314. DOI: https://doi.org/10.1097/ADM.0000000000000314
Saloner B, Levin J, Chang HY, et al.: Changes in buprenorphine-naloxone and opioid pain reliever prescriptions after the affordable care act Medicaid expansion. JAMA Netw Open. 2018; 1(4): e181588. DOI: 10.1001/jamanetworkopen.2018.1588. DOI: https://doi.org/10.1001/jamanetworkopen.2018.1588
Published
How to Cite
Issue
Section
License
Copyright 2005-2024, Weston Medical Publishing, LLC
All Rights Reserved
